{"transactions":[{"id":686610,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrants (right to buy)","published_at":"2026-08-14T23:39:28.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":101010,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant."}],"balance_after":101010,"derivative":{"exercise_price":1.1,"exercise_date":"2026-08-14","expiration_date":"2031-08-14","underlying":"Common Stock","underlying_shares":101010},"source":{"system":"sec-edgar","filing":"0001649989-26-000009","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000164998926000009/primary_doc.xml","form_type":"4"}},{"id":686609,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T23:39:28.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":101010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant."}],"balance_after":106956,"source":{"system":"sec-edgar","filing":"0001649989-26-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000164998926000009/primary_doc.xml","form_type":"4"}},{"id":703960,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-23T23:49:45.000Z","date":"2026-07-21","kind":"grant","planned":false,"acquired":true,"shares":210078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted to Mr. Kenyon on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan and the Issuer's standard form of stock option agreement thereunder. The option vests and becomes exercisable in full on July 21, 2027, subject to Mr. Kenyon's continuing service with the Issuer through such vesting date."}],"balance_after":210078,"derivative":{"exercise_price":1.4304,"exercise_date":"2027-07-21","expiration_date":"2036-07-21","underlying":"Common Stock","underlying_shares":210078},"source":{"system":"sec-edgar","filing":"0001649989-26-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000164998926000007/primary_doc.xml","form_type":"4"}},{"id":1397803,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-30T20:53:23.000Z","date":"2024-09-26","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.6892,"value":28446.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024."}],"balance_after":5946,"source":{"system":"sec-edgar","filing":"0001415889-24-024093","document":"form4-09302024_080919.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000141588924024093/form4-09302024_080919.xml","form_type":"4"}},{"id":1563197,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-22T21:00:22.000Z","date":"2024-03-20","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances."}],"balance_after":12500,"derivative":{"exercise_price":6.78,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-008974","document":"form4-03222024_050315.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000141588924008974/form4-03222024_050315.xml","form_type":"4"}},{"id":2743871,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Common Stock","published_at":"2021-04-20T23:54:00.000Z","date":"2021-04-20","kind":"purchase","acquired":true,"shares":10000,"price":1.83,"value":18300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within a $1.00 range. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":18926,"source":{"system":"sec-edgar","filing":"0001209191-21-027683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919121027683/doc4.xml","form_type":"4"}},{"id":3012799,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-05T22:48:01.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":3668984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in four equal installments beginning on October 1, 2021 such that the option shall be vested in full on October 1, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date, and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":3668984,"derivative":{"exercise_price":0.71,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":3668984},"source":{"system":"sec-edgar","filing":"0001209191-20-053875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919120053875/doc4.xml","form_type":"4"}},{"id":3078630,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-21T22:09:42.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in four equal installments beginning on July 17, 2021 such that the option shall be vested in full on July 17, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date, and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":450000,"derivative":{"exercise_price":1.58,"expiration_date":"2030-07-17","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-20-043224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919120043224/doc4.xml","form_type":"4"}},{"id":3199112,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T21:55:41.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":216435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall vest in four equal installments beginning on March 19, 2021 such that the option shall be vested in full on March 19, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date, and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":216435,"derivative":{"exercise_price":0.54,"expiration_date":"2030-03-19","underlying":"Common Stock","underlying_shares":216435},"source":{"system":"sec-edgar","filing":"0001209191-20-020512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919120020512/doc4.xml","form_type":"4"}},{"id":3393542,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Common Stock","published_at":"2019-10-15T21:08:09.000Z","date":"2019-09-18","kind":"sale","acquired":false,"shares":1350,"price":1.7,"value":2295.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units (\"RSUs\"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 - $1.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":8926,"source":{"system":"sec-edgar","filing":"0001209191-19-053184","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919119053184/doc4a.xml","form_type":"4/A","original_submission_date":"2019-09-23"}},{"id":3407667,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Common Stock","published_at":"2019-09-23T21:09:16.000Z","date":"2019-09-18","kind":"sale","acquired":false,"shares":1350,"price":1.7,"value":2295.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units (\"RSUs\"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 - $1.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":80863,"source":{"system":"sec-edgar","filing":"0001209191-19-050468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919119050468/doc4.xml","form_type":"4"}},{"id":3414837,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-13T21:04:12.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in four equal annual installments beginning on September 12, 2020 such that the option shall be vested in full on September 12, 2023, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in the event of a change in control as defined in the Issuer's 2015 Equity Incentive Plan, subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":450000,"derivative":{"exercise_price":1.75,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-19-049497","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919119049497/doc4.xml","form_type":"4"}},{"id":3649241,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-20T01:24:42.000Z","date":"2019-02-19","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in four equal installments beginning on February 19, 2020 such that the option shall be vested in full on February 19, 2023, subject to the Reporting Person providing continuous service to the Issuer on each such date.  Vesting may be accelerated in the event of (a) a change in control as defined in the Issuer's 2015 Equity Incentive Plan and (b) the achievement of certain pre-defined corporate objectives, in each case subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":800000,"derivative":{"exercise_price":1.32,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001209191-19-011378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919119011378/doc4.xml","form_type":"4"}},{"id":3667812,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Common Stock","published_at":"2019-02-09T01:14:42.000Z","date":"2019-02-07","kind":"purchase","acquired":true,"shares":25000,"price":0.8952,"value":22380.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the Reporting Person's sales of shares at $0.89 per share on September 18, 2018 to cover withholding taxes, as reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on September 18, 2018. The Reporting Person has paid to the Issuer $8.19, which represents the full amount of the profit realized in connection with this short-swing transaction, less transaction costs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8823 - $0.8952, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":82213,"source":{"system":"sec-edgar","filing":"0001209191-19-008782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919119008782/doc4.xml","form_type":"4"}},{"id":3812484,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Common Stock","published_at":"2018-09-18T20:56:21.000Z","date":"2018-09-18","kind":"sale","acquired":false,"shares":10100,"price":0.872,"value":8807.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units (\"RSUs\"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.855 - $0.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 21,739 shares of the Issuer's common stock subject to RSUs that will vest on 9/15/2019, subject to continued service through such date."}],"balance_after":57213,"source":{"system":"sec-edgar","filing":"0001209191-18-051494","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919118051494/doc4.xml","form_type":"4"}},{"id":3852903,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres, CFO, Treas & Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-03T21:09:19.000Z","date":"2018-08-01","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in four equal installments beginning on August 1, 2019 such that the option shall be vested in full on August 1, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such date.  Vesting may be accelerated in the event of (a) a change in control as defined in the Issuer's 2015 Equity Incentive Plan and (b) the achievement of certain pre-defined corporate objectives, in each case subject to the Reporting Person providing continuous service to the Issuer through such event."}],"balance_after":500000,"derivative":{"exercise_price":0.86,"expiration_date":"2028-08-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-18-045340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919118045340/doc4.xml","form_type":"4"}},{"id":4121568,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Secretary"}}],"security":"Common Stock","published_at":"2017-12-26T22:04:42.000Z","date":"2017-12-22","kind":"sale","acquired":false,"shares":26165,"price":1.13,"value":29566.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units (\"RSUs\"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,478 shares of the Issuer's common stock subject to RSUs that will vest 50% on each of the third and fourth year anniversaries of the 9/15/15 grant date, subject to continued service through such date.  The vesting of RSUs reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on December 22, 2016 was accelerated such that 100% of the shares underling those RSUs vested on December 21, 2017."}],"balance_after":67313,"source":{"system":"sec-edgar","filing":"0001209191-17-067229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919117067229/doc4.xml","form_type":"4"}},{"id":4513107,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Secretary"}}],"security":"Common Stock","published_at":"2016-12-22T23:07:48.000Z","date":"2016-12-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares underlying this restricted stock unit award vests in two equal installments on each of December 21, 2017 and December 21, 2018, in each case subject to the Reporting Person's continuous service to the Issuer through each such date. In addition, 100% of the shares underlying the restricted stock unit award will satisfy the time-based vesting restrictions upon the occurrence of a change of control, subject to continued service through such event."}],"balance_after":93478,"source":{"system":"sec-edgar","filing":"0001209191-16-156585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000120919116156585/doc4.xml","form_type":"4"}}]}